Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +62

Bleakley Financial Group LLC Takes $1.89 Million Position in Agilent ...

📈 Bleakley Financial Group LLC purchased 16,543 shares of Agilent Technologies valued at approximately $1.89 million in the first quarter.

📊 Multiple institutional investors including Fiduciary Trust Co and NorthCrest Asset Management increased their stakes by over 1.6% in recent quarters.

💰 Agilent reported Q2 revenue of $1.83 billion, representing a 10% year-over-year increase that surpassed analyst expectations.

📉 The company beat earnings estimates with $1.49 EPS compared to the consensus forecast of $1.41 per share.

🎯 TD Cowen raised its price target to $155 and maintained a 'buy' rating on Agilent Technologies stock.

📈 HSBC lowered its price objective to $165 but retained a 'buy' rating for the medical research firm.

🔭 Management provided FY 2026 earnings guidance ranging from $6.00 to $6.10 per share.

💵 Agilent declared a quarterly dividend of $0.255 per share with an ex-dividend date of June 30th.

📉 The stock trades at a P/E ratio of 27.34 with a market capitalization of $38.45 billion.

🛡️ The company maintains a low debt-to-equity ratio of 0.43 and a current ratio of 2.10.

Bullish Signals
  • Agilent Technologies reported revenue of $1.83 billion, which represents a 10% year-over-year increase and beat analyst expectations of $1.80 billion.
  • The company posted earnings per share of $1.49, topping the consensus estimate of $1.41 by $0.08.
  • TD Cowen lifted its price objective to $155.00 and assigned a 'buy' rating in a recent research report.
  • Wall Street Zen upgraded Agilent from a 'hold' to a 'buy' rating, reflecting improved analyst sentiment.
  • Barclays increased its price target to $150.00 and gave the stock an 'overweight' rating.
  • The company achieved a net margin of 19.55% and a return on equity of 24.33% during the reported quarter.
  • Institutional investors such as Fiduciary Trust Co, NorthCrest Asset Management, and Freestone Capital Holdings increased their positions by over 1.6% in recent quarters.
  • Agilent Technologies has set forward guidance for FY 2026 EPS between $6.00 and $6.10, aligning with analyst predictions of $6.00.
Risk Factors
  • HSBC Financial Group lowered its price target on Agilent Technologies from $180.00 to $165.00 in a recent report.
  • Jefferies Financial Group initiated coverage with a 'hold' rating and set a lower price objective of $135.00.
Full Analysis
Bleakley Financial Group LLC established a new position in Agilent Technologies, Inc. (NYSE:A) during the first quarter, purchasing 16,543 shares valued at approximately $1.89 million. Several other institutional investors, including Fiduciary Trust Co and NorthCrest Asset Management, also increased their holdings in the medical research company during the third and fourth quarters, signaling continued institutional interest. Wall Street analysts have recently issued mixed but generally positive ratings on Agilent shares. TD Cowen raised its price objective to $155 with a 'buy' rating, while HSBC lowered its target to $165 but maintained a 'buy' stance. The consensus average target price stands at $159.35, supported by a majority of analysts holding 'buy' or 'strong buy' ratings. Agilent reported strong financial results for the quarter ending May 27th, with revenue reaching $1.83 billion, a 10% year-over-year increase that beat analyst expectations. The company posted earnings per share of $1.49 against a consensus of $1.41, achieving a net margin of 19.55%. Management has provided forward guidance for FY 2026 EPS between $6.00 and $6.10. The stock currently trades with a market capitalization of $38.45 billion and a P/E ratio of 27.34. Agilent maintains a healthy balance sheet with a debt-to-equity ratio of 0.43 and recently declared a quarterly dividend of $0.255 per share, payable on July 22nd to shareholders of record as of June 30th.